Traws Pharma, Inc.(TRAW)Earnings, Financials & Key RatiosTraws Pharma, Inc. (TRAW) stock price & volume — 10-year historical chart
Investment Thesis • Updated 2026Q2
Negative: The company's cash runway is critically depleted with only $3.1M in cash remaining against a history of consistent quarterly free cash flow outflows exceeding $4M.
Traws Pharma, Inc. (TRAW) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Traws Pharma, Inc. (TRAW) EPS & revenue vs analyst estimates — last 4 quarters
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 15, 2026 | $0.53vs $0.92+42.4% | —vs $3M |
| Q2 2026 | Apr 15, 2026 | $0.71vs $1.22+42.0% | —vs $60,000 |
| Q3 2025 | Aug 14, 2025 | $0.11vs $8.75+98.7% | $3Mvs $60,000+4455.0% |
| Q2 2025 | May 15, 2025 | $2.09vs $8.04+126.0% | $57,000vs $60,000-5.0% |
Recent stock market news and headlines for Traws Pharma, Inc. (TRAW)
Resubmission of updated data package to MHRA, expected in 3Q 2026, to enable Phase 2a human influenza Challenge study to proceed Resubmission of updated data package to MHRA, expected in 3Q 2026, to enable Phase 2a human influenza Challenge study to proceed
Traws Pharma Inc. (NASDAQ:TRAW) shares are trading lower on Monday as the company faces regulatory challenges regarding its influenza treatment program.
Key metrics vs top competitors for Traws Pharma, Inc. (TRAW)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $0.70 | $6.38M | 0.85 | 1134.51% | 328.67% | — | — | |
| $522.25 | $132.84B | 34.09 | 9.57% | 35.4% | 23.93% | — | |
| $40.09 | $8.23B | -14.47 | — | — | -68.16% | — | |
| $136.36 | $169.3B | 20.11 | 2.39% | 30.99% | 42.33% | — | |
| $22.25 | $1.64B | 6.74 | 18.52% | 118.91% | 47.59% | — | |
| $4.88 | $390.53M | -2.52 | — | — | -57.01% | — |
Traws Pharma, Inc. (TRAW) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Traws Pharma, Inc. (TRAW) SEC filings — annual & quarterly reports (10-K, 10-Q)
May 27, 2026·SEC
May 26, 2026·SEC
May 15, 2026·SEC
Get notified when TRAW posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Traws Pharma, Inc. (TRAW) stock FAQ — growth, dividends, profitability & financials explained
Traws Pharma, Inc. (TRAW) reported $2.8M in revenue for fiscal year 2025. This represents a 88% increase from $1.5M in 2011.
Traws Pharma, Inc. (TRAW) grew revenue by 1134.5% over the past year. This is strong growth.
Traws Pharma, Inc. (TRAW) reported a net loss of $23.9M for fiscal year 2025.
Traws Pharma, Inc. (TRAW) had negative free cash flow of $2.59B in fiscal year 2025, likely due to heavy capital investments.
